{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:37:29Z","timestamp":1760204249659},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1007\/s11938-006-0041-4","type":"journal-article","created":{"date-parts":[[2007,6,18]],"date-time":"2007-06-18T15:54:18Z","timestamp":1182182058000},"page":"221-233","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety of biologics in inflammatory bowel disease"],"prefix":"10.1007","volume":"9","author":[{"given":"Wojciech","family":"Blonski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary R.","family":"Lichtenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"41_CR1","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1136\/gut.2003.025452","volume":"53","author":"WJ Sandborn","year":"2004","unstructured":"Sandborn WJ, Faubion WA: Biologics in inflammatory bowel disease: How much progress have we made?\n                           Gut 2004, 53:1366\u20131373. Comprehensive review of the use of biologics compounds in treatment of IBD.","journal-title":"Gut"},{"key":"41_CR2","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1053\/gast.2002.33426","volume":"122","author":"WJ Sandborn","year":"2002","unstructured":"Sandborn WJ, Targan SR: Biologic therapy of inflammatory bowel disease. Gastroenterology 2002, 122:1592\u20131608. Very interesting recent original paper presenting the data regarding efficacy and safety of infliximab in patients with UC.","journal-title":"Gastroenterology"},{"key":"41_CR3","first-page":"38","volume":"XXIX","author":"S Brown","year":"2005","unstructured":"Brown S, Abreu M: Biologic therapies in inflammatory bowel disease. Practical Gastroenterology 2005, XXIX:38\u201363.","journal-title":"Practical Gastroenterology"},{"key":"41_CR4","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462\u20132476.","journal-title":"N Engl J Med"},{"key":"41_CR5","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1053\/gast.2000.18160","volume":"119","author":"KA Papadakis","year":"2000","unstructured":"Papadakis KA, Targan SR: Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000, 119:1148\u20131157.","journal-title":"Gastroenterology"},{"key":"41_CR6","unstructured":"Remicade\u00ae [package insert]. Horsham, PA: Centocor; 2005."},{"key":"41_CR7","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","volume":"2","author":"SB Hanauer","year":"2004","unstructured":"Hanauer SB, Wagner CL, Bala M, et al.: Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn\u2019s disease. Clin Gastroenterol Hepatol 2004, 2:542\u2013553. Very comprehensive original paper on the development of antibodies to infliximab.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"41_CR8","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med 2003, 348:601\u2013608.","journal-title":"N Engl J Med"},{"key":"41_CR9","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet 2002, 359:1541\u20131549.","journal-title":"Lancet"},{"key":"41_CR10","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, et al.: Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med 2004, 350:876\u2013885.","journal-title":"N Engl J Med"},{"key":"41_CR11","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1111\/j.1572-0241.2002.07093.x","volume":"97","author":"WJ Sandborn","year":"2002","unstructured":"Sandborn WJ, Hanauer SB: Infliximab in the treatment of Crohn\u2019s disease: a user\u2019s guide for clinicians. Am J Gastroenterol 2002, 97:2962\u20132972.","journal-title":"Am J Gastroenterol"},{"key":"41_CR12","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1136\/gut.52.12.1728","volume":"52","author":"H Tilg","year":"2003","unstructured":"Tilg H, Vogelsang H, Ludwiczek O, et al.: A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 2003, 52:1728\u20131733.","journal-title":"Gut"},{"key":"41_CR13","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent. N Engl J Med 2001, 345:1098\u20131104.","journal-title":"N Engl J Med"},{"key":"41_CR14","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1053\/j.gastro.2004.02.070","volume":"126","author":"P Rutgeerts","year":"2004","unstructured":"Rutgeerts P, Van Assche G, Vermeire S: Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004, 126:1593\u20131610.","journal-title":"Gastroenterology"},{"key":"41_CR15","unstructured":"Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000, 49:1-51."},{"key":"41_CR16","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1053\/gast.2001.28703","volume":"121","author":"JD Lewis","year":"2001","unstructured":"Lewis JD, Bilker WB, Brensinger C, et al.: Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001, 121:1080\u20131087.","journal-title":"Gastroenterology"},{"key":"41_CR17","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1002\/1097-0142(19910401)67:7<2015::AID-CNCR2820670731>3.0.CO;2-R","volume":"67","author":"A Ekbom","year":"1991","unstructured":"Ekbom A, Helmick C, Zack M, Adami HO: Extracolonic malignancies in inflammatory bowel disease. Cancer 1991, 67:2015\u20132019.","journal-title":"Cancer"},{"key":"41_CR18","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1572-0241.1999.01012.x","volume":"94","author":"P Karlen","year":"1999","unstructured":"Karlen P, Lofberg R, Brostrom O, et al.: Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol 1999, 94:1047\u20131052.","journal-title":"Am J Gastroenterol"},{"key":"41_CR19","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/0016-5085(94)90807-9","volume":"107","author":"PG Persson","year":"1994","unstructured":"Persson PG, Karlen P, Bernell O, et al.: Crohn\u2019s disease and cancer: a population-based cohort study. Gastroenterology 1994, 107:1675\u20131679.","journal-title":"Gastroenterology"},{"key":"41_CR20","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1111\/j.1572-0241.2000.02316.x","volume":"95","author":"EV Loftus","year":"2000","unstructured":"Loftus EV, Tremaine WJ, Habermann TM, et al.: Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 2000, 95:2308\u20132312.","journal-title":"Am J Gastroenterol"},{"key":"41_CR21","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z","volume":"91","author":"CN Bernstein","year":"2001","unstructured":"Bernstein CN, Blanchard JF, Kliewer E, Wajda A: Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001, 91:854\u2013862.","journal-title":"Cancer"},{"key":"41_CR22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/gast.2000.16487","volume":"119","author":"D Palli","year":"2000","unstructured":"Palli D, Trallori G, Bagnoli S, et al.: Hodgkin\u2019s disease risk is increased in patients with ulcerative colitis. Gastroenterology 2000, 119:647\u2013653.","journal-title":"Gastroenterology"},{"key":"41_CR23","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/gut.2004.049460","volume":"54","author":"A Kandiel","year":"2005","unstructured":"Kandiel A, Fraser AG, Korelitz BI, et al.: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005, 54:1121\u20131125.","journal-title":"Gut"},{"key":"41_CR24","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","volume":"117","author":"P Rutgeerts","year":"1999","unstructured":"Rutgeerts P, D\u2019Haens G, Targan S, et al.: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn\u2019s disease. Gastroenterology 1999, 117:761\u2013769.","journal-title":"Gastroenterology"},{"key":"41_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","volume":"126","author":"JF Colombel","year":"2004","unstructured":"Colombel JF, Loftus EV, Tremaine WJ, et al.: The safety profile of infliximab in patients with Crohn\u2019s disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004, 126:19\u201331.","journal-title":"Gastroenterology"},{"key":"41_CR26","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1111\/j.1572-0241.2004.30186.x","volume":"99","author":"JA Katz","year":"2004","unstructured":"Katz JA, Antoni C, Keenan GF, et al.: Outcome of pregnancy in women receiving infliximab for the treatment of Crohn\u2019s disease and rheumatoid arthritis. Am J Gastroenterol 2004, 99:2385\u20132392.","journal-title":"Am J Gastroenterol"},{"key":"41_CR27","doi-asserted-by":"publisher","first-page":"W1034","DOI":"10.1053\/j.gastro.2005.01.048","volume":"128","author":"GR Lichtenstein","year":"2005","unstructured":"Lichtenstein GR, Cohen R, Feagan B, et al.: Safety of infliximab and other Crohn\u2019s disease therapies\u2014updated TREAT registry data with over 10,000 patientsyears of follow-up [abstract]. Gastroenterology 2005, 128:W1034.","journal-title":"Gastroenterology"},{"key":"41_CR28","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0140-6736(97)80083-9","volume":"349","author":"WA Stack","year":"1997","unstructured":"Stack WA, Mann SD, Roy AJ, et al.: Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn\u2019s disease. Lancet 1997, 349:521\u2013524.","journal-title":"Lancet"},{"key":"41_CR29","doi-asserted-by":"publisher","first-page":"A655","DOI":"10.1016\/S0016-5085(00)70134-X","volume":"118","author":"B Feagan","year":"2000","unstructured":"Feagan B, Sandborn W, Baker J, et al.: A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn\u2019s disease [abstract]. Gastroenterology 2000, 118:A655.","journal-title":"Gastroenterology"},{"key":"41_CR30","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1053\/gast.2001.24042","volume":"120","author":"WJ Sandborn","year":"2001","unstructured":"Sandborn WJ, Feagan BG, Hanauer SB, et al.: An engineered human antibody to TNF (CDP571) for active Crohn\u2019s disease: a randomized double-blind placebocontrolled trial. Gastroenterology 2001, 120:1330\u20131338.","journal-title":"Gastroenterology"},{"key":"41_CR31","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1136\/gut.2003.035253","volume":"53","author":"WJ Sandborn","year":"2004","unstructured":"Sandborn WJ, Feagan BG, Radford-Smith G, et al.: CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn\u2019s disease: a randomised, double blind, placebo controlled trial. Gut 2004, 53:1485\u20131493.","journal-title":"Gut"},{"key":"41_CR32","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1046\/j.1365-2036.1997.00251.x","volume":"11","author":"RC Evans","year":"1997","unstructured":"Evans RC, Clarke L, Heath P, et al.: Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. Aliment Pharmacol Ther 1997, 11:1031\u20131035.","journal-title":"Aliment Pharmacol Ther"},{"key":"41_CR33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1046\/j.1365-2036.2003.01414.x","volume":"17","author":"P Rutgeerts","year":"2003","unstructured":"Rutgeerts P, Lemmens L, Van Assche G, et al.: Treatment of active Crohn\u2019s disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 2003, 17:185\u2013192.","journal-title":"Aliment Pharmacol Ther"},{"key":"41_CR34","unstructured":"Enbrel\u00ae [package insert]. Collegeville, PA: Wyeth Pharmaceuticals; 2005."},{"key":"41_CR35","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1111\/j.1572-0241.2001.04705.x","volume":"96","author":"G D\u2019Haens","year":"2001","unstructured":"D\u2019Haens G, Swijsen C, Noman M, et al.: Etanercept in the treatment of active refractory Crohn\u2019s disease: a single-center pilot trial. Am J Gastroenterol 2001, 96:2564\u20132568.","journal-title":"Am J Gastroenterol"},{"key":"41_CR36","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1053\/gast.2001.28674","volume":"121","author":"WJ Sandborn","year":"2001","unstructured":"Sandborn WJ, Hanauer SB, Katz S, et al.: Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121:1088\u20131094.","journal-title":"Gastroenterology"},{"key":"41_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1053\/gast.2002.30770","volume":"122","author":"D Hommes","year":"2002","unstructured":"Hommes D, van den Blink B, Plasse T, et al.: Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn\u2019s disease. Gastroenterology 2002, 122:7\u201314.","journal-title":"Gastroenterology"},{"key":"41_CR38","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/j.1365-2036.2004.02285.x","volume":"20","author":"TA Winter","year":"2004","unstructured":"Winter TA, Wright J, Ghosh S, et al.: Intravenous CDP870, a PEGylated Fab\u2019 fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn\u2019s disease: an exploratory study. Aliment Pharmacol Ther 2004, 20:1337\u20131346.","journal-title":"Aliment Pharmacol Ther"},{"key":"41_CR39","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","volume":"129","author":"S Schreiber","year":"2005","unstructured":"Schreiber S, Rutgeerts P, Fedorak R, et al.: A randomized, placebo-controlled trial of certolizumab pegol (CDP870) in active Crohn\u2019s disease. Gastroenterology 2005, 129:807\u2013818.","journal-title":"Gastroenterology"},{"key":"41_CR40","doi-asserted-by":"crossref","first-page":"A112","DOI":"10.1053\/j.gastro.2004.11.036","volume":"128","author":"W Sandborn","year":"2005","unstructured":"Sandborn W, Hanauer S, Lucas M, et al.: Induction and maintenance of clinical remission and response in subjects with Crohn\u2019s disease treated during a 6-month open-label period with fully human anti-TNFalpha monoclonal antibody adalimumab (humira) [abstract]. Gastroenterology 2005, 128:A112-A113.","journal-title":"Gastroenterology"},{"key":"41_CR41","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1053\/j.gastro.2004.05.010","volume":"127","author":"S Hanauer","year":"2004","unstructured":"Hanauer S, Lukas M, MacIntosh D, et al.: A randomized, double-blind, placebo-controlled trial of the human anti-TNF-alpha monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn\u2019s disease [abstract]. Gastroenterology 2004, 127:332.","journal-title":"Gastroenterology"},{"key":"41_CR42","doi-asserted-by":"publisher","first-page":"A53","DOI":"10.1053\/j.gastro.2004.01.047","volume":"126","author":"W Sandborn","year":"2004","unstructured":"Sandborn W, Hanauer S, Loftus E, et al.: An openlabel study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn\u2019s disease [abstract]. Gastroenterology 2004, 126:A53-A54.","journal-title":"Gastroenterology"},{"key":"41_CR43","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0016-5085(98)70418-4","volume":"114","author":"BR Yacyshyn","year":"1998","unstructured":"Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al.: A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn\u2019s disease. Gastroenterology 1998, 114:1133\u20131142.","journal-title":"Gastroenterology"},{"key":"41_CR44","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1053\/gast.2001.24015","volume":"120","author":"S Schreiber","year":"2001","unstructured":"Schreiber S, Nikolaus S, Malchow H, et al.: Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn\u2019s disease. Gastroenterology 2001, 120:1339\u20131346.","journal-title":"Gastroenterology"},{"key":"41_CR45","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/gut.51.1.30","volume":"51","author":"BR Yacyshyn","year":"2002","unstructured":"Yacyshyn BR, Chey WY, Goff J, et al.: Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn\u2019s disease. Gut 2002, 51:30\u201336.","journal-title":"Gut"},{"key":"41_CR46","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1046\/j.1365-2036.2002.01341.x","volume":"16","author":"BR Yacyshyn","year":"2002","unstructured":"Yacyshyn BR, Barish C, Goff J, et al.: Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn\u2019s disease. Aliment Pharmacol Ther 2002, 16:1761\u20131770.","journal-title":"Aliment Pharmacol Ther"},{"key":"41_CR47","first-page":"A112","volume":"128","author":"WY Chey","year":"2005","unstructured":"Chey WY, Konecny M, Rydzewska G, et al.: Two phase 3 studies of Alicaforsen (ISIS-2302), an antisense oligonucleotide to human ICAM-1, in the treatment of moderate to severe Crohn\u2019s disease [abstract]. Gastroenterology 2005, 128:A112.","journal-title":"Gastroenterology"},{"key":"41_CR48","first-page":"A74","volume":"128","author":"S Van Deventer","year":"2005","unstructured":"Van Deventer S, Volfova M, Flisiak R, et al.: A phase 2 dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left sided ulcerative colitis [abstract]. Gastroenterology 2005, 128:A74.","journal-title":"Gastroenterology"},{"key":"41_CR49","first-page":"A74","volume":"128","author":"P Miner","year":"2005","unstructured":"Miner P, Nichols T, Schwartz H, et al.: A phase 2 trial to assess the safety and efficacy of two dose formulations of alicaforsen enema compared with 4g mesalamine enema for acute ulcerative colitis [abstract]. Gastroenterology 2005, 128:A74.","journal-title":"Gastroenterology"},{"key":"41_CR50","doi-asserted-by":"crossref","unstructured":"Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody. Drugs R D 2004, 5:102\u2013107.","DOI":"10.2165\/00126839-200405020-00007"},{"key":"41_CR51","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1053\/gast.2001.26260","volume":"121","author":"FH Gordon","year":"2001","unstructured":"Gordon FH, Lai CW, Hamilton MI, et al.: A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn\u2019s disease. Gastroenterology 2001, 121:268\u2013274.","journal-title":"Gastroenterology"},{"key":"41_CR52","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa020732","volume":"348","author":"S Ghosh","year":"2003","unstructured":"Ghosh S, Goldin E, Gordon FH, et al.: Natalizumab for active Crohn\u2019s disease. N Engl J Med 2003, 348:24\u201332.","journal-title":"N Engl J Med"},{"key":"41_CR53","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa043335","volume":"353","author":"WJ Sandborn","year":"2005","unstructured":"Sandborn WJ, Colombel JF, Enns R, et al.: Natalizumab induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med 2005, 353:1912\u20131925.","journal-title":"N Engl J Med"},{"key":"41_CR54","doi-asserted-by":"publisher","first-page":"A463","DOI":"10.1053\/j.gastro.2004.02.072","volume":"126","author":"B Sands","year":"2004","unstructured":"Sands B, Kozarek R, Spainhour J, et al.: Safety and tolerability of natalizumab in patients concurrently receiving infliximab in a phase 2 study of active Crohn\u2019s disease [abstract]. Gastroenterology 2004, 126:A463.","journal-title":"Gastroenterology"},{"key":"41_CR55","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1046\/j.1365-2036.2002.01205.x","volume":"16","author":"FH Gordon","year":"2002","unstructured":"Gordon FH, Hamilton MI, Donoghue S, et al.: A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002, 16:699\u2013705.","journal-title":"Aliment Pharmacol Ther"},{"key":"41_CR56","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1056\/NEJMoa051586","volume":"353","author":"G Van Assche","year":"2005","unstructured":"Van Assche G, Van Ranst M, Sciot R, et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease. N Engl J Med 2005, 353:362\u2013368.","journal-title":"N Engl J Med"},{"key":"41_CR57","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1056\/NEJMoa051847","volume":"353","author":"A Langer-Gould","year":"2005","unstructured":"Langer-Gould A, Atlas SW, Green AJ, et al.: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005, 353:375\u2013381.","journal-title":"N Engl J Med"},{"key":"41_CR58","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1056\/NEJMoa051782","volume":"353","author":"BK Kleinschmidt-DeMasters","year":"2005","unstructured":"Kleinschmidt-DeMasters BK, Tyler KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005, 353:369\u2013374.","journal-title":"N Engl J Med"},{"key":"41_CR59","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMc055235","volume":"353","author":"B Adelman","year":"2005","unstructured":"Adelman B, Sandrock A, Panzara MA: Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med 2005, 353:432\u2013433.","journal-title":"N Engl J Med"},{"key":"41_CR60","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa042982","volume":"352","author":"BG Feagan","year":"2005","unstructured":"Feagan BG, Greenberg GR, Wild G, et al.: Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005, 352:2499\u20132507.","journal-title":"N Engl J Med"},{"key":"41_CR61","unstructured":"Inc. MP. http:\/\/investor.millennium.com\/phoenix.zhtml?c= 80159&p=irol-newsmediaArticle&ID=333736&highlight= Accessed December 15, 2005."},{"key":"41_CR62","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1365-2036.2005.02526.x","volume":"22","author":"A Kasran","year":"2005","unstructured":"Kasran A, Boon L, Wortel CH, et al.: Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn\u2019s disease. Aliment Pharmacol Ther 2005, 22:111\u2013122.","journal-title":"Aliment Pharmacol Ther"},{"key":"41_CR63","first-page":"A75","volume":"126","author":"S Plevy","year":"2004","unstructured":"Plevy S, Salzberg B, Van Assche G, et al.: A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid-refractory ulcerative colitis: results of a phase I study. Gastroenterology 2004, 126:A75.","journal-title":"Gastroenterology"},{"key":"41_CR64","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1046\/j.1365-2036.2003.01603.x","volume":"17","author":"P Rutgeerts","year":"2003","unstructured":"Rutgeerts P, Van Deventer S, Schreiber S: Review article: the expanding role of biological agents in the treatment of inflammatory bowel disease\u2014focus on selective adhesion molecule inhibition. Aliment Pharmacol Ther 2003, 17:1435\u20131450.","journal-title":"Aliment Pharmacol Ther"},{"key":"41_CR65","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1053\/gast.1997.v113.pm9247454","volume":"113","author":"SJ van Deventer","year":"1997","unstructured":"van Deventer SJ, Elson CO, Fedorak RN: Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn\u2019s disease. Crohn\u2019s Disease Study Group. Gastroenterology 1997, 113:383\u2013389.","journal-title":"Gastroenterology"},{"key":"41_CR66","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1053\/gast.2000.20196","volume":"119","author":"S Schreiber","year":"2000","unstructured":"Schreiber S, Fedorak RN, Nielsen OH, et al.: Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn\u2019s disease. Crohn\u2019s Disease IL-10 Cooperative Study Group. Gastroenterology 2000, 119:1461\u20131472.","journal-title":"Gastroenterology"},{"key":"41_CR67","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1053\/gast.2000.20229","volume":"119","author":"RN Fedorak","year":"2000","unstructured":"Fedorak RN, Gangl A, Elson CO, et al.: Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn\u2019s disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000, 119:1473\u20131482.","journal-title":"Gastroenterology"},{"key":"41_CR68","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1136\/gut.49.1.42","volume":"49","author":"JF Colombel","year":"2001","unstructured":"Colombel JF, Rutgeerts P, Malchow H, et al.: Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn\u2019s disease. Gut 2001, 49:42\u201346.","journal-title":"Gut"},{"key":"41_CR69","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0016-5085(99)70550-0","volume":"117","author":"BE Sands","year":"1999","unstructured":"Sands BE, Bank S, Sninsky CA, et al.: Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn\u2019s disease. Gastroenterology 1999, 117:58\u201364.","journal-title":"Gastroenterology"},{"key":"41_CR70","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1046\/j.1365-2036.2002.01179.x","volume":"16","author":"BE Sands","year":"2002","unstructured":"Sands BE, Winston BD, Salzberg B, et al.: Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn\u2019s disease. Aliment Pharmacol Ther 2002, 16:399\u2013406.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-006-0041-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11938-006-0041-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-006-0041-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-006-0041-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:15:48Z","timestamp":1659093348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11938-006-0041-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["41"],"URL":"https:\/\/doi.org\/10.1007\/s11938-006-0041-4","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]},"assertion":[{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}